Santhera Pharmaceuticals Net Income Per Share Over Time
| SANN Stock | CHF 16.46 0.46 2.88% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Santhera Pharmaceuticals Performance and Santhera Pharmaceuticals Correlation. Santhera |
Cross Equities Net Income Per Share Analysis
Compare Santhera Pharmaceuticals and related stocks such as Molecular Partners, Ascom Holding AG, and Addex Therapeutics Net Income Per Share Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MOLN | 0.3665 | 0.3665 | 0.3665 | 0.3665 | (0.15) | (0.0076) | (0.9111) | (1.219) | (1.7496) | (1.6946) | (2.5105) | (2.0572) | 3.6296 | (1.8914) | (1.588) | (1.83) | (1.73) |
| ASCN | (2.495) | 0.6667 | 0.606 | 1.0665 | 1.0982 | 0.686 | (4.0655) | 0.7206 | 0.5951 | 0.0139 | 0.1806 | 0.3751 | 0.306 | 0.4845 | 0.103 | 0.12 | 0.11 |
| ADXN | (4.0951) | (4.1907) | (3.4149) | (1.5952) | (0.1778) | (0.3874) | (0.276) | (0.2535) | (0.0706) | (0.56) | (0.4819) | (0.4518) | (0.4604) | (0.1421) | 0.0719 | 0.0647 | 0.068 |
| EVE | (533) | (28.3361) | (18.2304) | (17.2874) | (15.3288) | (18.927) | (18.9122) | (20.2163) | (9.482) | (7.0211) | (9.4916) | (11.7233) | (10.1299) | (19.5013) | 0.1448 | 0.13 | 0.14 |
| NWRN | (5.2886) | (0.8873) | (0.2911) | (0.6168) | (0.7958) | (1.6627) | (1.0374) | (0.324) | (0.8426) | (1.1324) | (1.1767) | (0.835) | (0.9803) | (0.9092) | 0.8535 | 0.77 | 0.81 |
| SHLTN | 0.1327 | 0.38 | (0.6969) | 0.2152 | 0.0793 | (1.5872) | (1.0578) | 0.2295 | 0.9655 | 0.5422 | 0.0265 | (1.0046) | (0.0052) | (0.5435) | (1.7141) | (1.97) | (1.87) |
| DOCM | 0.8646 | 2.7224 | 1.927 | (4.568) | 2.114 | 1.0149 | (2.8153) | (6.945) | (6.1385) | (6.0428) | (14.9503) | (23.4034) | (15.8804) | 7.0483 | (8.247) | (9.48) | (9.96) |
| CLTN | 2.8247 | 1.4437 | 2.2753 | 3.1279 | 3.7057 | 3.1621 | 4.096 | 4.5193 | 3.1633 | 3.3526 | 1.3777 | 5.3068 | 4.3516 | 1.9994 | 3.4253 | 3.94 | 4.16 |
Santhera Pharmaceuticals and related stocks such as Molecular Partners, Ascom Holding AG, and Addex Therapeutics Net Income Per Share description
My Equities
My Current Equities and Potential Positions
| Santhera Pharmaceuticals Holding | SANN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Hohenrainstrasse 24, Pratteln, |
| Exchange | SIX Swiss Exchange |
CHF 16.46
Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.